Instrument Inactif

Communiqués DIS LAB USD0.001 Nasdaq

Actions

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

15/05	Windtree Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
17/04	Windtree Therapeutics à la recherche d'acquisitions	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Windtree Therapeutics : May'24 Corporate Presentation	30/05	PU
Windtree Therapeutics Regains Compliance with Nasdaq	07/05	AQ
Windtree Therapeutics : April'24 Corporate Presentation	24/04	PU
Windtree Therapeutics Announces Reverse Stock Split	18/04	AQ
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates	17/04	AQ
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing	08/04	AQ
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	01/02	AQ
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives	31/01	AQ
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company	25/01	AQ
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION	18/01	AQ
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region	17/01	AQ
WINDTREE THERAPEUTICS ANNOUNCES REDUCTION IN ARRYTHMIAS IN A NEW STUDY WITH ISTAROXIME AND A PURE SERCA2A ACTIVATOR	03/01	AQ
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator	02/01	AQ
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock	18/12	AQ
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent	16/11	AQ
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates	09/11	AQ
Windtree to Present at the Sidoti Micro Cap Conference on November 16th	08/11	AQ
Windtree to Present at the ThinkEquity Conference on October 19th in New York City	12/10/23	AQ
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th	10/10/23	AQ
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th	03/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués DIS LAB USD0.001 Nasdaq

Actions

Communiqués

Filtres